Literature DB >> 11476169

PET imaging of hypoxia.

J S Lewis1, M J Welch.   

Abstract

Hypoxia in tumors has been related to poor response to conventional therapies. This paper will discuss the methods, both invasive and non-invasive, used to determine hypoxia levels within tumors. PET imaging with two lead compounds 18F-fluoromisonidazole (18FMISO) and Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone (Cu-ATSM) and their relative effectiveness in delineating hypoxic regions will be discussed. The advantages of Cu-ATSM-PET over existing imaging agents will be discussed along with its potential application as a direct- and/or surrogate marker for the determination of oncological hypoxia in vivo.

Entities:  

Mesh：

Year:  2001        PMID： 11476169

Source DB:  PubMed          Journal:  Q J Nucl Med        ISSN： 1125-0135


  15 in total

Review 1.  Quantitative multimodality imaging in cancer research and therapy.

Authors:  Thomas E Yankeelov; Richard G Abramson; C Chad Quarles
Journal:  Nat Rev Clin Oncol       Date:  2014-08-12       Impact factor: 66.675

Review 2.  Imaging hypoxia to improve radiotherapy outcome.

Authors:  Michael R Horsman; Lise Saksø Mortensen; Jørgen B Petersen; Morten Busk; Jens Overgaard
Journal:  Nat Rev Clin Oncol       Date:  2012-11-13       Impact factor: 66.675

Review 3.  Magnetic resonance imaging of tumor oxygenation and metabolic profile.

Authors:  Murali C Krishna; Shingo Matsumoto; Keita Saito; Masayuki Matsuo; James B Mitchell; Jan H Ardenkjaer-Larsen
Journal:  Acta Oncol       Date:  2013-08-19       Impact factor: 4.089

4.  Dosimetry of 60/61/62/64Cu-ATSM: a hypoxia imaging agent for PET.

Authors:  Richard Laforest; Farrokh Dehdashti; Jason S Lewis; Sally W Schwarz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-03-23       Impact factor: 9.236

5.  Intracellular hypoxia of tumor tissue estimated by noninvasive electron paramagnetic resonance oximetry technique using paramagnetic probes.

Authors:  Atsuko Matsumoto; Ken-ichiro Matsumoto; Shingo Matsumoto; Fuminori Hyodo; Anastasia L Sowers; Janusz W Koscielniak; Nallathamby Devasahayam; Sankaran Subramanian; James B Mitchell; Murali C Krishna
Journal:  Biol Pharm Bull       Date:  2011       Impact factor: 2.233

6.  Species dependence of [64Cu]Cu-Bis(thiosemicarbazone) radiopharmaceutical binding to serum albumins.

Authors:  Nathan E Basken; Carla J Mathias; Alexander E Lipka; Mark A Green
Journal:  Nucl Med Biol       Date:  2008-01-30       Impact factor: 2.408

7.  One-stop-shop tumor imaging: buy hypoxia, get lactate free.

Authors:  Ashley A Manzoor; Thies Schroeder; Mark W Dewhirst
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808

8.  Elucidation of the human serum albumin (HSA) binding site for the Cu-PTSM and Cu-ATSM radiopharmaceuticals.

Authors:  Nathan E Basken; Carla J Mathias; Mark A Green
Journal:  J Pharm Sci       Date:  2009-06       Impact factor: 3.534

Review 9.  Current molecular imaging positron emitting radiotracers in oncology.

Authors:  Aizhi Zhu; Hyunsuk Shim
Journal:  Nucl Med Mol Imaging       Date:  2011-02-01

10.  Practical dynamic contrast enhanced MRI in small animal models of cancer: data acquisition, data analysis, and interpretation.

Authors:  Stephanie L Barnes; Jennifer G Whisenant; Mary E Loveless; Thomas E Yankeelov
Journal:  Pharmaceutics       Date:  2012       Impact factor: 6.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.